Skip to main content
. Author manuscript; available in PMC: 2011 Oct 15.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(20):7992–8002. doi: 10.1158/0008-5472.CAN-10-0585

Figure 6. Androgens Inhibit Tubulin Expression in Prostate Cancer Cells.

Figure 6

Panel A; Prostate cancer cells LNCaP, LNCaP TβRII and CWR22, were treated with DHT (1nM; for 72hrs) and tubulin expression was evaluated by Western blotting using GAPDH as internal normalizing control. Panel B; LNCaP TβRII and CWR22 cells were treated with DHT (1nM) with or without TGF-β (5ng/ml) for 72hrs. Tubulin expression was detected by immunofluorescence (red); nuclei were stained by DAPI (blue). Panel C illustrates the emerging mechanistic scenario: microtubules facilitate AR nuclear translocation and enhance downstream AR transcriptional activity in prostate cancer cells. Microtubule targeting chemotherapy blocks this pathway and suppresses AR signaling, via a negative feedback mechanism; AR signaling inhibits tubulin expression thus impairing the cytoskeleton structure and organization.